{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:43Z","timestamp":1740126823136,"version":"3.37.3"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Padiatr"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background Once daily intravenous (iv) treatment with tobramycin for\n                    Pseudomonas aeruginosa infection in patients with cystic fibrosis (pwCF) is\n                    frequently monitored by measuring tobramycin trough levels (TLs). Although the\n                    necessity of these TLs is recently questioned in pwCF without renal impairment,\n                    no study has evaluated this so far. The aim of this observational study was to\n                    evaluate the frequency of increased tobramycin TLs in pwCF treated with a once\n                    daily tobramycin dosing protocol.<\/jats:p><jats:p>\n          Methods Patient records of all consecutive once daily iv tobramycin\n                    courses in 35 pwCF between 07\/2009 and 07\/2019 were analyzed for\n                    tobramycin level, renal function, co-medication and comorbidity.<\/jats:p><jats:p>\n          Results Eight elevated TLs (2.9% of 278 courses) were recorded in\n                    four patients, two with normal renal function. One of these resolved without\n                    adjustment of tobramycin dosages suggesting a test timing or laboratory error.\n                    In the other patient the elevated tobramycin level decreased after tobramycin\n                    dosage adjustment. Six of the elevated levels occurred in two patients with\n                    chronic renal failure. In 15 other patients with reduced glomerular filtration\n                    rate (GFR) (36 courses) but normal range creatinine no case of elevated\n                    tobramycin trough levels was detected. Neither cumulative tobramycin dosages nor\n                    concomitant diabetes or nutritional status were risk factors for elevated\n                    TLs.<\/jats:p><jats:p>\n          Conclusion Our data show that elevated tobramycin TLs are rare but cannot\n                    be excluded, so determination of tobramycin TLs is still recommended for\n                    safety.<\/jats:p>","DOI":"10.1055\/a-2244-6903","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:21:33Z","timestamp":1706574093000},"page":"116-122","source":"Crossref","is-referenced-by-count":0,"title":["Necessity of Tobramycin trough Levels in Once Daily Iv-Treatment in\n                    Patients with Cystic Fibrosis"],"prefix":"10.1055","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-3624","authenticated-orcid":false,"given":"Anne","family":"Schlegtendal","sequence":"additional","affiliation":[{"name":"Department of pediatrics, Ruhr-Universit\u00e4t Bochum Medizinische\n                    Fakult\u00e4t, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Rettberg","sequence":"additional","affiliation":[{"name":"Department of pediatrics, Ruhr-Universit\u00e4t Bochum Medizinische\n                    Fakult\u00e4t, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Maier","sequence":"additional","affiliation":[{"name":"Department of pediatrics, Ruhr-Universit\u00e4t Bochum Medizinische\n                    Fakult\u00e4t, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4307-4232","authenticated-orcid":false,"given":"Folke","family":"Brinkmann","sequence":"additional","affiliation":[{"name":"Department of pediatrics, Ruhr-Universit\u00e4t Bochum Medizinische\n                    Fakult\u00e4t, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cordula","family":"Koerner-Rettberg","sequence":"additional","affiliation":[{"name":"Paediatrics, Medizinische Fakult\u00e4t Universit\u00e4t Luebeck,\n                    L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary\n                    exacerbations of cystic fibrosis\u2013the TOPIC study: a randomised\n                    controlled trial","volume":"365","author":"A Smyth","year":"2005","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/jac\/dkl328","article-title":"Once-daily tobramycin in cystic fibrosis: better for clinical outcome than\n                    thrice-daily tobramycin but more resistance development?","volume":"58","author":"O Burkhardt","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1592\/phco.30.1.95","article-title":"Extended-interval once-daily dosing of aminoglycosides in adult and pediatric\n                    patients with cystic fibrosis","volume":"30","author":"W A Prescott","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5863\/1551-6776-21.3.239","article-title":"Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A\n                    Pharmacist Approach","volume":"21","author":"J T Zobell","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10928-013-9348-7","article-title":"Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin\n                    dosing among children with cystic fibrosis","volume":"41","author":"C M Sherwin","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak\n                    concentration to minimal inhibitory concentration","volume":"155","author":"R D Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"CD002009","DOI":"10.1002\/14651858.CD002009.pub7","article-title":"Once-daily versus multiple-daily dosing with intravenous aminoglycosides for\n                    cystic fibrosis","author":"J Bhatt","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2022-003545","article-title":"Is there a multinational consensus of tobramycin prescribing and monitoring for\n                    cystic fibrosis? Survey of current therapeutic drug monitoring practices in\n                    USA\/Canada, UK\/Ireland, and Australia\/New Zealand","author":"R Larcombe","year":"2022","journal-title":"Eur J Hosp Pharm"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40620-015-0179-z","article-title":"Renal diseases in adults with cystic fibrosis: a 40 year single centre\n                    experience","volume":"28","author":"M J Wilcock","year":"2015","journal-title":"J Nephrol"},{"key":"ref10","first-page":"347","article-title":"CF Lung Disease \u2013 a German S3 Guideline: Module 2: Diagnostics and\n                    Treatment in Chronic Infection with Pseudomonas aeruginosa","volume":"72","author":"C Schwarz","year":"2018","journal-title":"Pneumologie"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jcf.2009.08.004","article-title":"Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a\n                    review","volume":"8","author":"F Ratjen","year":"2009","journal-title":"J Cyst Fibros"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/MCP.0b013e32833eebfd","article-title":"Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity","volume":"16","author":"A Prayle","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e00737","DOI":"10.1128\/AAC.00737-21","article-title":"Population pharmacokinetic modeling and dosing simulations of tobramycin in\n                    pediatric patients with cystic fibrosis","volume":"65","author":"A Praet","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1365-2125.2007.03045.x","article-title":"Target concentration intervention is needed for tobramycin dosing in paediatric\n                    patients with cystic fibrosis \u2013 a population pharmacokinetic study","volume":"65","author":"S Hennig","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jppr.1145","article-title":"Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia\n                    and the UK","volume":"46","author":"P Paviour","year":"2016","journal-title":"J Pharm Pract Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-014-0211-9","article-title":"Comparing dosage adjustment methods for once-daily tobramycin in paediatric and\n                    adolescent patients with cystic fibrosis","volume":"54","author":"S Hennig","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1128\/AAC.01131-16","article-title":"Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis","volume":"60","author":"M A Barras","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40262-018-0707-9","article-title":"Monitoring of Tobramycin Exposure: What is the Best Estimation Method and\n                    Sampling Time for Clinical Practice?","volume":"58","author":"Y Gao","year":"2019","journal-title":"Clinical Pharmacokinetics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jcf.2006.05.015","article-title":"Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis\n                    \u2013 caution with trough concentrations","volume":"6","author":"K P Coulthard","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1128\/aac.31.4.594","article-title":"Cumulative and acute toxicity of repeated high-dose tobramycin treatment in\n                    cystic fibrosis","volume":"31","author":"S S Pedersen","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/adc.78.6.536","article-title":"Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for\n                    pseudomonas exacerbations in cystic fibrosis","volume":"78","author":"P Vic","year":"1998","journal-title":"Arch Dis Child"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5863\/1551-6776-21.3.239","article-title":"Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A\n                    Pharmacist Approach","volume":"21","author":"J T Zobell","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them\n                    optimally","volume":"45","author":"G L Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5863\/1551-6776-28.1.63","article-title":"Review of Tobramycin Dosing in Pediatric Patients With Cystic Fibrosis","volume":"28","author":"T A Imburgia","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1128\/AAC.02654-15","article-title":"Assessing predictive performance of published population pharmacokinetic models\n                    of intravenous tobramycin in pediatric patients","volume":"60","author":"C Bloomfield","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1053\/j.jrn.2017.05.006","article-title":"Cystic Fibrosis: A Risk Condition for Renal Disease","volume":"27","author":"D Santoro","year":"2017","journal-title":"J Ren Nutr"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jcf.2017.11.001","article-title":"Prevalence and characteristics of chronic kidney disease among Danish adults\n                    with cystic fibrosis","volume":"17","author":"K H Berg","year":"2018","journal-title":"J Cyst Fibros"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/FTD.0b013e31822c78e9","article-title":"Renal impairment in cystic fibrosis patients due to repeated intravenous\n                    aminoglycoside use","volume":"39","author":"M Al-Aloul","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/thx.2006.067595","article-title":"Survey of acute renal failure in patients with cystic fibrosis in the UK","volume":"62","author":"C Bertenshaw","year":"2007","journal-title":"Thorax"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40262-019-00761-5","article-title":"Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric\n                    Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis","volume":"58","author":"R L Crass","year":"2019","journal-title":"Clinical Pharmacokinetics"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1002\/ppul.25066","article-title":"Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients\n                    with cystic fibrosis","volume":"55","author":"S Anasemon","year":"2020","journal-title":"Ped Pulmonol"}],"container-title":["Klinische P\u00e4diatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2244-6903.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:22:52Z","timestamp":1730809372000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2244-6903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":31,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,2,22]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2244-6903","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0300-8630","1439-3824"],"issn-type":[{"type":"print","value":"0300-8630"},{"type":"electronic","value":"1439-3824"}],"subject":[],"published":{"date-parts":[[2024,1,29]]}}}